Phase 3 clinical trials of NT-501, an encapsulated cell therapy delivering CNTF, demonstrated significant reduction in disease progression for macular telangiectasia type 2 patients, with up to 52% reduction in ellipsoid zone loss.
Modern randomized controlled trials (RCTs) in IBD face challenges including trial design, patient selection, and endpoint assessment, impacting result interpretation.